On Monday 24th July 2018 the Presidency of the British Association for Psychopharmacology was handed over to Professor Allan Young:
Professor Allan Young was formerly Chair of the Royal College of Psychiatrists Psychopharmacology Committee [he remains on this committee now as a Member].
As an RCPsych committee member, professor Allan Young gives this generalised declaration of competing interests:
“Paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders”.
He also outlines his research links with various commercial companies. Professor Allan Young confirms that he has no shares in pharmaceutical companies.
Professor Allan Young gives this declaration of 24 January 2017 on the British Association for Psychopharmacology.
This is a clip of the 52nd Maudsley debate, 13 May 2015:
Professor Allan Young is one of the authors and editors of The Maudsley Prescribing Guidelines which are described as providing:
“up-to-date information, expert guidance on prescribing practice in mental health” and as “the world’s leading clinical resource for evidence-based prescribing in day-to-day clinical practice and for formulating prescribing policy”.